RSR13 Investigator Presented With National Tumor Foundation Research Award At Society for Neuro-Oncology Annual Meeting

RSR13 Investigator Presented With National Tumor Foundation Research Award At
Society for Neuro-Oncology Annual Meeting 


KEYSTONE, Colo., Nov. 15  /PRNewswire-FirstCall/ -- Allos Therapeutics, Inc. 
announced today that John H. Suh, M.D., Clinical Director, Radiation Oncology,
Brain Tumor Institute at the Cleveland Clinic, has received the National Tumor
Foundation Clinical Research Award at the Eighth Annual Meeting of The Society
for Neuro-Oncology in Keystone, Colorado, for his leading role in the pivotal
Phase 3 clinical trial of Allos Therapeutics' investigational drug RSR13
(efaproxaril).  Dr. Suh co-chaired the randomized, open-label study that
compared standard whole brain radiation therapy (WBRT) with supplemental oxygen
with or without RSR13 in patients with brain metastases.  RSR13 is an
investigational radiation sensitizer being developed by Allos Therapeutics that
facilitates the release of oxygen from hemoglobin to hypoxic (oxygen-deprived)
tumor tissues, making radiation therapy more effective.

"The National Brain Tumor Foundation is pleased to honor Dr. Suh with this
award.  His groundbreaking work suggests that the survival of patients with
brain metastases can be extended and gives hope to patients for whom there are
few treatment options," said Janis C. Brewer, Executive Director, National Brain
Tumor Foundation. "The National Brain Tumor Foundation supports the development
of better treatments for people who suffer from brain metastases and applauds
Dr. Suh and his colleagues for their contributions to this important area of
cancer research."

Dr. Suh stated: "I am very gratified to receive this award in recognition of our
clinical research with RSR13.  Treatment of brain metastases is an exciting and
evolving field and our work with RSR13 demonstrates that bringing together tumor
biology and radiotherapy can yield promising new therapies.  We are very
encouraged by these favorable results and hope to see this product advance to
treat patients who have limited therapeutic options."

Previously reported results of the RSR13 Phase 3 trial show the risk of death in
all patients treated was reduced by 22 percent when RSR13 was added to whole
brain radiation therapy in patients with brain metastases.  Among breast cancer
patients, RSR13's therapeutic benefit was even more potent and showed a near
doubling of the median survival (4.57 vs 8.67 months).

"We congratulate Dr. Suh and his colleagues in receiving this award, which
recognizes their outstanding contributions to the treatment of patients with
brain metastases," said Michael E. Hart, President and Chief Executive Officer
of Allos Therapeutics.

Allos Therapeutics, Inc. is currently submitting a rolling New Drug Application
(NDA) to the U.S. Food and Drug Administration (FDA) for RSR13 for the treatment
of patients with breast cancer that has metastasized to the brain.  The company
expects to complete its NDA submission in December 2003.

About Brain Metastases in Breast Cancer Patients

Approximately 200,000 women and 1,300 men will be diagnosed with breast cancer
in the United States in 2003. Approximately 20-to-30 percent of these breast
cancer patients will develop brain metastases. The most common type of brain
cancer, brain metastases are tumors that have spread to the brain from a
malignant tumor in another part of the body. This condition occurs in
approximately one out of five cancer patients, most often in patients with
breast cancer or non-small cell lung cancer. There are approximately 175,000
annual cases of brain metastases in the U.S. Standard whole-brain radiation is
the primary palliative therapy for treating patients with brain metastases and
has been shown to prevent or reduce complications and to increase survival.

About National Brain Tumor Foundation

The National Brain Tumor Foundation is a nationwide non-profit organization
serving people whose lives have been affected by brain tumors. They are
dedicated to promoting a cure for brain tumors, improving the quality of life
and giving hope to the brain tumor community by funding meaningful research and
providing patient resources, timely information and education.

About Allos Therapeutics, Inc.

Allos Therapeutics, Inc. is a biopharmaceutical company focused on developing
and commercializing innovative drugs for improving cancer treatments. The
company's lead clinical candidate, RSR13 (efaproxiral), is a synthetic small
molecule that has the potential to sensitize hypoxic (oxygen deprived) tumor
tissues and enhance the efficacy of standard radiation therapy.  In addition,
Allos is developing PDX, a novel small molecule cytotoxic injectable antifolate
(DHFR inhibitor) being developed for non-small cell lung cancer, mesothelioma
and non-Hodgkin's lymphoma. For more information, please visit the company's web
site at: http://www.allos.com/.

This announcement contains forward-looking statements that involve risks and
uncertainties.  Future events may differ materially from those discussed herein
due to a number of factors, including, but not limited to, risks and
uncertainties related to the company's ability to complete the submission of its
NDA to the FDA on schedule and in accordance with regulatory requirements, to
adequately demonstrate the safety and efficacy of RSR13 for use as a radiation
sensitizer in the treatment of breast cancer that has metastasized to the brain
and any other type of cancer, and its ability to obtain regulatory approval for
RSR13, as well as other risks and uncertainties detailed from time to time in
the company's SEC filings, including its Annual Report on Form 10-K for the year
ended December 31, 2002.  All forward-looking statements are based on
information currently available to the company on the date hereof, and the
company assumes no responsibility to update such statements. 

DATASOURCE: Allos Therapeutics, Inc.



CONTACT:  Monique M. Greer VP, Corporate Communications and Investor

Relations, [phone] (direct), ; or Lazar Partners

Limited (media), Fern Lazar, +1-/First Call Analyst: 



Web site:  http://www.allos.com/

Copyright